Background Aromatase inhibitors are associated with consistent improvements in disease-
free survival but not in overall survival. We conducted a literature-based meta-analysis of …

Purpose To develop evidence-based guidelines, based on a systematic review, for
endocrine therapy for postmenopausal women with hormone receptor–positive breast …

Cardiovascular (CV) toxicity is a potential short-or long-term complication of various
anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have …

In the last half of the century, advances in the systemic therapy of cancer, including
chemotherapy, hormonal therapy, targeted therapy, and immunotherapy have been …

Background: The association between aromatase inhibitors and cardiovascular outcomes
among women with breast cancer is controversial. Given the discrepant findings from …

ABSTRACT Background Aromatase inhibitors (AIs) have been associated with
cardiovascular disease in adjuvant randomized controlled trials (RCTs) comparing these …

The landscape of early breast cancer has changed dramat-ically with significant
advancements in early screening and diagnosis and curative-intent therapies. Indeed …

АВ—атриовентрикулярный (ая) АГ—артериальная гипертензия АД—артериальное
давление АТ—артериальный тромбоз АТО—атеротромботические осложнения АТФ …

Purpose This phase III randomized open-label clinical trial was designed to evaluate the
efficacy and safety of the steroidal aromatase inactivator exemestane versus the …

Objective To investigate the effect of endocrine therapies on a wide range of specific clinical
cardiovascular disease outcomes in women with a history of non-metastatic breast cancer …